Form 4: Modular Medical Executive Paul DiPerna Granted Options Tied to Key Milestones

Paul DiPerna, a Director and Officer at Modular Medical, received options to purchase common stock, vesting upon achievement of specific regulatory and manufacturing milestones related to the MODDi pump product.

Summary

• Paul DiPerna, a Director, Officer, and 10% Owner of Modular Medical, Inc., was granted two options to purchase common stock on April 24, 2025.
• Each option is for 200,000 shares of common stock at an exercise price of $0.94.
• The first option vests if the company receives FDA 510(K) clearance for its MODDi pump product by October 31, 2025; otherwise, it terminates on November 1, 2025.
• The second option vests if the company's manufacturing line is validated for the MODDi pump product with a capacity to serve 6,000 patients by March 15, 2026; otherwise, it terminates on March 16, 2026.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of options is a standard practice, and the vesting conditions are tied to positive milestones. However, the risk of the options not vesting exists.

Positives

• The granting of options to a key executive aligns their interests with the company's success in achieving regulatory and manufacturing milestones.
• Successful achievement of the milestones would likely be viewed positively by the market.

Risks

• Failure to obtain FDA clearance by October 31, 2025, will result in the termination of one of the options.
• Failure to validate the manufacturing line by March 15, 2026, will result in the termination of the other option.

Future Outlook

The vesting of the options is directly tied to the company achieving key regulatory and manufacturing milestones for its MODDi pump product, indicating a focus on these objectives in the near term.

Industry Context

In the medical device industry, regulatory approvals and manufacturing capabilities are critical milestones. Tying executive compensation to these milestones is a common practice to incentivize progress and align management's interests with shareholder value.

Comparison to Industry Standards

• Companies like Insulet (PODD) and Tandem Diabetes Care (TNDM) also focus on innovative insulin delivery systems.
• The vesting conditions tied to FDA clearance and manufacturing validation are standard practices in the medical device industry, reflecting the importance of these milestones for commercial success.
• The size of the option grants is within the typical range for executive compensation in similarly sized companies.

Stakeholder Impact

• Shareholders: The vesting of the options is tied to milestones that could increase shareholder value.
• Employees: Successful achievement of the milestones could lead to increased job security and potential for further growth.
• Customers: Successful development and manufacturing of the MODDi pump product could provide a new treatment option for patients.

Next Steps

• The company will need to achieve FDA 510(K) clearance for its MODDi pump product by October 31, 2025.
• The company will need to validate its manufacturing line for the MODDi pump product with a capacity to serve 6,000 patients by March 15, 2026.

Key Dates

Keywords

options, Paul DiPerna, Modular Medical, MODDi pump, FDA clearance, manufacturing validation, Form 4, beneficial ownership